Shopping Cart
- Remove All
Your shopping cart is currently empty
Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $197 | In Stock | |
| 5 mg | $516 | In Stock | |
| 10 mg | $828 | In Stock | |
| 25 mg | $1,230 | In Stock | |
| 50 mg | $1,650 | In Stock |
| Description | Vilobelimab (CaCP-29) is a human-mouse chimeric IgG antibody targeting human complement component 5a, a C5a inhibitor that inhibits neutrophil activation, and can be used for the study of systemic inflammation caused by SARS-CoV-2 infection. |
| In vitro | Vilobelimab selectively neutralizes C5a in a dose-dependent manner without preventing the formation of membrane-attacking complexes and has not raised significant safety concerns in certain clinical studies in patients with severe sepsis and septic shock. [1] |
| Synonyms | IFX-1, IFX1, CaCP-29, CaCP29 |
| Cas No. | 2250440-41-4 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.